Results from Phase II study of CHR 2797 (Cell Therapeutics) for AML published in the Lancet Oncology

Results from the OPAL Phase II study of CHR 2797 (tosedostat), from Cell Therapeutics, in elderly patients with relapsed or refractory Acute Myeloid Leukemia (AML) have been published in the Lancet Oncology. Results were released in 2012. The trial showed that once-daily oral tosedostat resulted in a disease control rate of 51%. Subset analyses suggested the greatest benefit occurred in the difficult-to-treat patients with prior myelodysplastic syndrome or those that had received prior hypomethylating therapy. Adverse events were mild, predictable and manageable. See: "Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study." Prof Jorge Cortes et al. The Lancet Oncology, Early Online Publication, 28 February 2013 doi:10.1016/S1470-2045(13)70037-8